Download the free whitepaper: Unravelling the complexities of genomics-driven drug discovery

Genomics-driven drug discovery holds immense promise in developing targeted therapies by leveraging genetic and biomarker information to understand the root causes of diseases. However, the field faces significant hurdles.

In this whitepaper, we examine the obstacles of limited recontactability, scarcity of multi-omics data sets, lack of diversity in data, and the challenge of scaling research for rare diseases. By addressing these challenges and proposing strategies to address them, this whitepaper aims to chart a path by which we can harness the full potential of genomics-driven drug discovery.


whitepaper image
download icon

Download Whitepaper

Precision in practice: 

Harnessing polygenic risk scores for targeted metabolic dysfunction-associated steatohepatitis (MASH) therapies


What does the future of liver disease management look like? Unlock new insights into the role of genetics in MASH and how polygenic risk scores (PRS) are revolutionising treatment strategies.

Download our comprehensive whitepaper to explore:

  • The genetic underpinnings of MASH
  • Case studies and the latest research on genetic MASH
  • Strategies for incorporating PRS in clinical practice
  • Ethical and practical considerations in genetic-based treatments
MASH whitepaper social graphic